Palisade Bio releases virtual KOL Connect segment on PALI-2108

Palisade Bio (PALI) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, MD, FRCPC. Dr. Feagan is a Professor of Medicine, Epidemiology & Biostatistics at Western University, a practicing gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc. He is a founding member of the Stenosis Therapy and Antifibrotic Research Consortium, the founder of Robarts Clinical Trials, and globally recognized leaders in IBD clinical research. Dr. Feagan has directed more than 140 randomized controlled trials in Crohn’s disease and ulcerative colitis, developed widely used outcome measures including the Robarts Histopathology Index, and published extensively in the field. He is internationally recognized as a leading authority in FSCD and clinical trial design. As part of the segment, Dr. Feagan discussed FSCD and the challenges with current approved therapies, highlighting the significant unmet need for more effective therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on the novel approach of PALI-2108 and how it could potentially impact the overall treatment landscape. PALI-2108’s localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.